Oncology

A phase 2 trial reported 100% 3-year overall survival rates with frontline therapy consisting of lenalidomide, bortezomib, and dexamethasone in younger patients with multiple myeloma.

The FDA today approved the first non-invasive colorectal screening test to indicate the presence of certain abnormal growths that may be colorectal cancer or precursors to colon cancer.

Screening of newborn children for hepatitis C and new, more effective hepatitis C treatments may virtually eliminate the disease in the United States by 2036.

More than 90% of women in the program received timely follow-up care.

In a study that has the potential to change public health recommendations for breast cancer screening, researchers have validated the value of mammography in older women.

More than 90% of women in the program received timely follow-up care.

Just 20 or 30 years ago, mention of vitamin supplementation caused many health care professionals to talk about creating "expensive urine." Today, however, vitamin and nutrient supplementation has become an important health care intervention.

Researchers in Taiwan have found an increase in the risk for head and neck cancers among patients with diabetes mellitus (DM) equivalent to approximately 2.6 additional cases per 10,000 person-years in patients with DM versus patients without DM.

Biologics License Application filed for filgrastim by Sandoz.

Blood test three times more specific in detection of prostate cancer than prostate-specific antigen.

Survey finds an overwhelming number of seniors are unaware of what biosimilars are.

Sunscreen application to infant opossums leads to 10-fold reduction in pre-melanotic lesions.

Targeted therapies used in conjunction with chemotherapy may offer benefits to patients with triple-negative breast cancer.

A study indicates that BPA-induced cancers in female rats may lead to tumors with evidence of both genetic and epigenetic changes.

Researchers at the Dana-Farber Cancer Institute and Brigham and Women's Hospital have tested a nanomedicine technology in mice formulated to precisely target myeloma cancer cells with a novel bortezomib delivery system.

Study indicates hyperlipidaemia increases risk of breast cancer by 1.64 times.

Executive at Pfizer discusses the various regulatory roadblocks and market challenges for biosimilars in a Q&A with Specialty Pharmacy Times.

People with high levels of sedentary behavior are more susceptible to 3 types of cancer.

Diabetes control worsened for patients with diabetes who received or were receiving androgen deprivation therapy for prostate cancer.

Study finds cancer management guidelines need to be updated to account for patients with HIV.

Radiation oncologists and urologists surveyed indicate the primary treatment provided by the other specialty is being overused.

In addition to finding no association between aspirin use and reduced risk of breast cancer, researchers find non-breast cancer deaths higher among aspirin users.

Patients treated for Hodgkin's disease during childhood or adolescence have a greater risk of developing secondary breast cancer later in life, particularly if they receive radiotherapy during puberty.

Researchers in the United Kingdom have identified a blood test for circulating free DNA that may help physicians predict whether or not a patient with breast cancer is likely to respond to an initial round of chemotherapy, enabling earlier initiation of alternate treatments.

Peter Yu, MD, director, Palo Alto Medical Foundation, president-elect, ASCO, discusses results of a review that examined men's treatment decisions after seeing a rise in their PSA levels.

This National Cancer Institute video provides key facts and statistics on prostate cancer diagnosis and treatment.

This presentation by Michael S. Cookson, MD, MMHC, vice chairman and Hart Professor of Urologic Surgery at Vanderbilt University Medical Center, addresses prostate cancer treatment options for 6 common clinical scenarios.

Charles M. Perou, PhD, professor of genetics, pathology & laboratory medicine, UNC Lineberger Comprehensive Cancer Center, discusses a trial (CALGB 40601) presented at the 2014 ASCO Annual Meeting.